{"DataElement":{"publicId":"2959870","version":"1","preferredName":"Intervention Trial Study Protocol Document Classification Code StudyClassificationCategory","preferredDefinition":"A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation._The code that describes the type of primary outcome or endpoint that the study is designed to evaluate.","longName":"2959181v1.0:2959413v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"2959181","version":"1","preferredName":"Intervention Trial Study Protocol Document Classification Code","preferredDefinition":"A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.","longName":"2867669v1.0:2959131v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2867669","version":"1","preferredName":"Intervention Trial Study Protocol Document","preferredDefinition":"A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.:A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.:A rule which guides how an activity should be performed.:An organized collection of records that describe a particular body of data.","longName":"C16140:C63536:C42651:C19498","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intervention Trial","conceptCode":"C16140","definition":"A pre-clinical or clinical study in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions. The individuals are then followed and biomedical and/or health outcomes are assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Study","conceptCode":"C63536","definition":"A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Document","conceptCode":"C19498","definition":"A physical object, or electronic counterpart, that is characterized by containing writing which is meant to be human-readable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"694174B2-D8AB-D6FE-E040-BB89AD4374D5","latestVersionIndicator":"Yes","beginDate":"2009-05-06","endDate":null,"createdBy":"UMLLOADER_BRIDGPRD","dateCreated":"2009-05-06","modifiedBy":"ONEDATA","dateModified":"2009-05-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2959131","version":"1","preferredName":"Classification Code","preferredDefinition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:A symbol or combination of symbols which is given an arbitrary meaning within a systematized collection of concepts used for data representation.","longName":"C25161:C25162","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Code","conceptCode":"C25162","definition":"A symbol or combination of symbols which is assigned to the members of a collection.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FAFE50-1200-3106-E040-BB89AD432E40","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2222502","version":"1","preferredName":"UML DEFAULT CD","preferredDefinition":"Default Conceptual Domain for UML Loader","longName":"UML DEFAULT CD","context":"caCORE","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5E53F3B-47A4-52D1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2005-04-29","modifiedBy":"DWARZEL","dateModified":"2021-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB0E38-4F3A-D27E-E040-BB89AD43552F","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ZHANGW","dateModified":"2021-08-23","changeDescription":"8/23/2021wz: released for UML model cleanup project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2959413","version":"1","preferredName":"StudyClassificationCategory","preferredDefinition":"The code that describes the type of primary outcome or endpoint that the study is designed to evaluate.","longName":"2959413v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"ISO21090CDv1.0","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Bio-availability","valueDescription":"Bioavailability","ValueMeaning":{"publicId":"2959414","version":"1","preferredName":"Bioavailability","longName":"2959414","preferredDefinition":"The rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action (21CFR320.1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bioavailability","conceptCode":"C70913","definition":"The rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of action (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB36AF-7255-764C-E040-BB89AD433B5C","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-726B-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Bio-equivalence","valueDescription":"Bioequivalence","ValueMeaning":{"publicId":"2857215","version":"1","preferredName":"Bioequivalence","longName":"2857215","preferredDefinition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bioequivalence","conceptCode":"C71763","definition":"The absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Where there is an intentional difference in rate (e.g., in certain controlled release dosage forms), certain pharmaceutical equivalents or alternatives may be considered bioequivalent if there is no significant difference in the extent to which the active ingredient or moiety from each product becomes available at the site of drug action. This applies only if the difference in the rate at which the active ingredient or moiety becomes available at the site of drug action is intentional and is reflected in the proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug (21CFR320.1).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"661EB49B-B373-7D2B-E040-BB89AD4340DC","latestVersionIndicator":"Yes","beginDate":"2009-03-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-727C-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Efficacy","valueDescription":"Efficacy Study","ValueMeaning":{"publicId":"2579238","version":"1","preferredName":"Efficacy Study","longName":"2579238","preferredDefinition":"A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study. \r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Efficacy Study","conceptCode":"C49666","definition":"A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0293-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-08","modifiedBy":"REEVESD","dateModified":"2006-09-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-7285-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Pharmacodynamics","valueDescription":"Pharmacodynamics","ValueMeaning":{"publicId":"2959415","version":"1","preferredName":"Pharmacodynamics","longName":"2959415","preferredDefinition":"The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacodynamics","conceptCode":"C15720","definition":"The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB36AF-7290-764C-E040-BB89AD433B5C","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-72A6-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Pharmacokinetics","valueDescription":"Pharmacokinetics","ValueMeaning":{"publicId":"2562229","version":"1","preferredName":"Pharmacokinetics","longName":"2562229","preferredDefinition":"Pharmacokinetics","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacokinetics","conceptCode":"C15299","definition":"The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-C022-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-08-02","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-08-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-72B7-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Pharmacokinetics/dynamics","valueDescription":"Pharmacokinetics Pharmacodynamics","ValueMeaning":{"publicId":"2959416","version":"1","preferredName":"Pharmacokinetics Pharmacodynamics","longName":"2959416","preferredDefinition":"The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.:The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pharmacokinetics","conceptCode":"C15299","definition":"The characteristic movements of drugs within biological systems, as affected by absorption, distribution, binding, elimination, biotransformation, and excretion; particularly the rates of such movements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmacodynamics","conceptCode":"C15720","definition":"The study of the biochemical and physiological effects of drugs and the mechanisms of their actions, including the correlation of actions and effects of drugs with their chemical structure, also, such effects on the actions of a particular drug or drugs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB36AF-72C3-764C-E040-BB89AD433B5C","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-72D9-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Safety","valueDescription":"Safety","ValueMeaning":{"publicId":"2754175","version":"1","preferredName":"Safety","longName":"2754175","preferredDefinition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Safety","conceptCode":"C60828","definition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E629357-B3C8-2F1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-05-29","endDate":null,"createdBy":"UMLLOADER_CANANOLAB","dateCreated":"2008-05-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-72E2-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"},{"value":"Safety/Efficacy","valueDescription":"Safety Efficacy Study","ValueMeaning":{"publicId":"2959417","version":"1","preferredName":"Safety Efficacy Study","longName":"2959417","preferredDefinition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions.:A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Safety","conceptCode":"C60828","definition":"The state of being certain that adverse effects will not be caused by some agent under defined conditions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Efficacy Study","conceptCode":"C49666","definition":"A study of the relative therapeutic efficacy of treatment of a disease. Usually this is a Phase II or III study.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB36AF-72EE-764C-E040-BB89AD433B5C","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77FB36AF-7304-764C-E040-BB89AD433B5C","beginDate":null,"endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ONEDATA","dateModified":"2009-11-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008528","version":"1","preferredName":"Protocol Administration","preferredDefinition":"the management of a research protocol and its case report forms.","longName":"PROT_ADM","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1ECAD41-A932-34B1-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2433877","version":"1","preferredName":"Category","preferredDefinition":"Category; used informally to mean a class of things.","longName":"C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"062E16DD-4D2F-16F1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-28","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-28","modifiedBy":"ONEDATA","dateModified":"2005-11-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB36AF-7241-764C-E040-BB89AD433B5C","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ZHANGW","dateModified":"2021-07-22","changeDescription":"7/22/2021wz: released for UML model cleanup project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2958963","version":"1","longName":"COPPA","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2958964","version":"1","longName":"gov.nih.nci.COPPA.InformationModel","context":"NCIP"}]}],"AlternateNames":[{"name":"gov.nih.nci.COPPA.InformationModel.InterventionalStudyProtocol.classificationCode","type":"UML Qualified Attr","context":"NCIP"},{"name":"InterventionalStudyProtocol:classificationCode","type":"UML Class:UML Attr","context":"NCIP"}],"ReferenceDocuments":[{"name":"Data Element Intervention Trial Study Protocol Document Classification Code StudyClassificationCategory does not have Preferred Question Text","type":"Preferred Question Text","description":"Data Element Intervention Trial Study Protocol Document Classification Code StudyClassificationCategory does not have Preferred Question Text","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77FB6A87-9DF7-7536-E040-BB89AD4335D9","latestVersionIndicator":"Yes","beginDate":"2009-11-09","endDate":null,"createdBy":"UMLLOADER_COPPAPRD","dateCreated":"2009-11-09","modifiedBy":"ZHANGW","dateModified":"2021-08-23","changeDescription":"8/23/2021wz: released for UML model cleanup project.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}